Introduction to Arbitus 250 mg Tablet
The medication Arbitus 250 mg Tablet is employed as an anticancer agent in combination with prednisone for addressing prostate cancer that has metastasized in men. Typically prescribed for individuals unresponsive to alternative treatment modalities.
Uses of Arbitus 250 mg Tablet
- Metastatic castration-resistant prostate cancer
More Information about Arbitus 250 mg Tablet
Arbitus 250 mg Tablet is prescribed for treating prostate cancer that has metastasized to other parts of the body. It is typically administered to patients who show inadequate response to alternative treatment approaches.
Safety Advices for Arbitus 250 mg Tablet
Pregnancy
Usage of this medication is advised against during pregnancy in women.
Breast Feeding
The use of this medication is not recommended for women.
Alcohol
The interaction with alcohol is not established. It is recommended to consult your doctor before consuming this medication.
Side Effects of Arbitus 250 mg Tablet
Serious:
- Hypersensitivity
- Increased blood pressure
- Irregular heartbeat
- Swelling of ankles or feet
- Dizziness
Common:
- Nausea and vomiting
- Shortness of breath
- Urinary tract infection
- Increased cholesterol and triglycerides
- Anemia
- Hypokalemia
Word of Advice
Follow the doctor’s instructions when taking Arbitus 250 mg Tablet. Avoid exceeding the recommended dosage. If you encounter any adverse effects, consult your doctor. Complete the prescribed treatment course, and refrain from discontinuing the medication without consulting your doctor.
Therapeutic class: Antipyretic, Analgesics
Indications: To relieve pain and fever in children below 5 years of age.
References
- DailyMed – ZYTIGA- abiraterone acetate tablet ZYTIGA- abiraterone acetate tablet, film coated [Internet]. Dailymed.nlm.nih.gov. 2017 [cited 19 August 2017].
- Abiraterone: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2017 [cited 19 August 2017].
- Prescribing medicines in pregnancy database [Internet]. Therapeutic Goods Administration (TGA). 2017 [cited 19 August 2017].
Reviews
There are no reviews yet.